1e
19
1
49
2
2
18
1b
1d
18
2e
8c
1d
2 29
1d
25
Adam D Cohen, MD
78
8c
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
28
72
3
5f
Director, Myeloma Immunotherapy, University of Pennsylvania
55
Member, Abramson Cancer Center
74
Co-Director, Amyloidosis Program, University of Pennsylvania
11
Department: Medicine
4
1
b
1d
46
Contact information
53
4
3
3
3
2
4
b
1f
53
Perelman Center for Advanced Medicine
22 12th Floor, South Pavilion
16 Office #12-175
39 3400 Civic Center Blvd
Philadelphia, PA 19104
26
22 12th Floor, South Pavilion
16 Office #12-175
39 3400 Civic Center Blvd
Philadelphia, PA 19104
2e
Office: 215-615-5853
32 Fax: 215-615-5887
24
f
32 Fax: 215-615-5887
24
13
Education:
21 7 BA c
2b Harvard University, 1994.
21 7 MD c
33 University of Pennsylvania, 1999.
c
3
3
3
3
8d
Permanent link21 7 BA c
2b Harvard University, 1994.
21 7 MD c
33 University of Pennsylvania, 1999.
c
2 29
21
1e
1d
24
5e
13 Amyloidosis
16 POEMS syndrome
1f Monoclonal gammopathies
26 Waldenstrom's Macroglobulinemia
71
18 Cellular therapy
16 Phase I trials
12 CAR T cells
e 29
27
Description of Clinical Expertise
21 Multiple Myeloma13 Amyloidosis
16 POEMS syndrome
1f Monoclonal gammopathies
26 Waldenstrom's Macroglobulinemia
71
Description of Research Expertise
25 Cancer immunotherapy18 Cellular therapy
16 Phase I trials
12 CAR T cells
e 29
23
1ad Musa H, Mielnik M, Trudel S, Weisel K, Mockus-Daehn T, Ferron-Brady G, Hong Q, Ma Y, Pater S, Suchindran S, Zhou X, Richardson PG, Cohen AD*, Lowther DE*: Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma Haematologica Aug 2025 Notes: 2025 Aug 28. doi: 10.3324/haematol.2025.288203. Online ahead of print 27 *co-senior authors.
27c Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM: Long-Term (5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology 43(25): 2766-71, Sep 2025.
152 Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl DT, Cohen AD, Garfall AL, Waxman AJ, Kapur S, Stadtmauer EA, Adaniya SS, Longworth S: Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma. Haematologica 110(6): 1436-42, Jun 2025.
3b0 Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nature Medicine 31(4): 1134-1144, Apr 2025.
16d Stalker M, Garfall A, Cohen AD, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, Stadtmauer E, Megherea O, Waxman AJ: Safety and efficacy of teclistamab in patients with relapsed or refractory AL amyloidosis: a retrospective case series. European Journal of Haematology 114(3): 443-447, Mar 2025.
242 Costa LJ, Banerjee R, Mian H, Weisel KC, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J, Frigault MJ, Ye JC, van de Donk NWCJ, Voorhees PM, Puliafito B, Bahlis N, Popat R, Chng WJ, Ho PJ, Kaur G, Kapoor P, Du J, Schjesvold F, Berdeja J, Einsele H, Cohen AD, Mikhael J, Biru Y, Rajkumar SV, Lin Y, Martin TG, Chari A: International Myeloma Working Group Immunotherapy Committee Recommendation on Sequencing Immunotherapy for Treatment of Multiple Myeloma. Leukemia 39(3): 543-554, Mar 2025.
101 Hasanali ZS, Razzo B, Susanibar-Adaniya SP, Garfall AL, Stadtmauer EA, Cohen AD: CAR T cells in the treatment of Multiple Myeloma. Hematology/Oncology Clinics 38(2): 383-406, Apr 2024.
171 Elghawy O, Deshpande S, Sussman J, Garfall A, Cohen A, Kapur S, Susanibar-Adaniya S, Vogl D, Waxman A, Stadtmauer E: Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (auto-HCT) for multiple myeloma. Bone Marrow Transplantation 60(1): 64-68, Jan 2025.
12c Gaballa MR, Puglianini OC, Cohen A, Vogl D, Chung A, Ferreri CJ, Voorhees P, Hansen DK, Patel KK: BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Advances 9(5): 1171-1180, Mar 2025.
2c
7
1d
1f
Selected Publications
17c Yu KL, Ho M, Paruzzo L, Stella F, Patel H, Hasanali Z, Kapur S, Waxman AJ, Vogl DT, Stadtmauer EA, Fraietta JA, Ruella M, Cohen AD, Garfall AL, Susanibar-Adaniya S: Outcomes of relapse after teclistamab therapy in multiple myeloma. Blood Cancer Journal 15(1): 193. doi: 10.1038/s41408-025-01408-4. Nov 2025.1ad Musa H, Mielnik M, Trudel S, Weisel K, Mockus-Daehn T, Ferron-Brady G, Hong Q, Ma Y, Pater S, Suchindran S, Zhou X, Richardson PG, Cohen AD*, Lowther DE*: Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma Haematologica Aug 2025 Notes: 2025 Aug 28. doi: 10.3324/haematol.2025.288203. Online ahead of print 27 *co-senior authors.
27c Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM: Long-Term (5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology 43(25): 2766-71, Sep 2025.
152 Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl DT, Cohen AD, Garfall AL, Waxman AJ, Kapur S, Stadtmauer EA, Adaniya SS, Longworth S: Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma. Haematologica 110(6): 1436-42, Jun 2025.
3b0 Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nature Medicine 31(4): 1134-1144, Apr 2025.
16d Stalker M, Garfall A, Cohen AD, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, Stadtmauer E, Megherea O, Waxman AJ: Safety and efficacy of teclistamab in patients with relapsed or refractory AL amyloidosis: a retrospective case series. European Journal of Haematology 114(3): 443-447, Mar 2025.
242 Costa LJ, Banerjee R, Mian H, Weisel KC, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J, Frigault MJ, Ye JC, van de Donk NWCJ, Voorhees PM, Puliafito B, Bahlis N, Popat R, Chng WJ, Ho PJ, Kaur G, Kapoor P, Du J, Schjesvold F, Berdeja J, Einsele H, Cohen AD, Mikhael J, Biru Y, Rajkumar SV, Lin Y, Martin TG, Chari A: International Myeloma Working Group Immunotherapy Committee Recommendation on Sequencing Immunotherapy for Treatment of Multiple Myeloma. Leukemia 39(3): 543-554, Mar 2025.
101 Hasanali ZS, Razzo B, Susanibar-Adaniya SP, Garfall AL, Stadtmauer EA, Cohen AD: CAR T cells in the treatment of Multiple Myeloma. Hematology/Oncology Clinics 38(2): 383-406, Apr 2024.
171 Elghawy O, Deshpande S, Sussman J, Garfall A, Cohen A, Kapur S, Susanibar-Adaniya S, Vogl D, Waxman A, Stadtmauer E: Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (auto-HCT) for multiple myeloma. Bone Marrow Transplantation 60(1): 64-68, Jan 2025.
12c Gaballa MR, Puglianini OC, Cohen A, Vogl D, Chung A, Ferreri CJ, Voorhees P, Hansen DK, Patel KK: BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Advances 9(5): 1171-1180, Mar 2025.
2c